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Objective: To estimate the allele frequency of C9orf72
(G4C2) repeats in amyotrophic lateral sclerosis (ALS), fron-
totemporal lobar degeneration (FTLD), Alzheimer dis-
ease (AD), and Parkinson disease (PD).
Design: The number of repeats was estimated by a 2-step
genotyping strategy. For expansion carriers, we se-
quenced the repeat flanking regions and obtained APOE
genotypes and MAPT H1/H2 haplotypes.
Setting: Hospitals specializing in neurodegenerative dis-
orders.
Subjects: We analyzed 520 patients with FTLD, 389 pa-
tients with ALS, 424 patients with AD, 289 patients with
PD, 602 controls, 18 families, and 29 patients with PD
with the LRRK2 G2019S mutation.
Main Outcome Measure: The expansion frequency.
Results: Based on a prior cutoff (30 repeats), the ex-
pansion was detected in 9.3% of patients with ALS, 5.2%
of patients with FTLD, and 0.7% of patients with PD but
not in controls or patients with AD. It was significantly
associated with family history of ALS or FTLD and age
at onset of FTLD. Phenotype variation (ALS vs FTLD)
was not associated with MAPT, APOE, or variability in
the repeat flanking regions. Two patients with PD were
carriers of 39 and 32 repeats with questionable patho-
logical significance, since the 39-repeat allele does not
segregate with PD. No expansion or intermediate alleles
(20-29 repeats) were found among the G2019S carriers
and AD cases with TAR DNA-binding protein 43–
positive inclusions. Surprisingly, the frequency of the 10-
repeat allele was marginally increased in all 4 neurode-
generative diseases compared with controls, indicating
the presence of an unknown risk variation in theC9orf72
locus.
Conclusions: The C9orf72 expansion is a common cause
of ALS and FTLD, but not of AD or PD. Our study raises
concern about a reliable cutoff for the pathological re-
peat number, which is important in the utility of genetic
screening.
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A MYOTROPHIC LATERAL SCLE-rosis (ALS) and frontotem-poral lobar degeneration(FTLD) are fatal neurode-generative syndromes that
belong to the same clinicopathological
spectrum.1,2 Frontotemporal lobar degen-
eration is a primary dementia character-
ized by early behavioral, language, and ex-
trapyramidal changes, while symptoms of
ALS are the result of the degeneration of
motor neurons. Both syndromes may oc-
cur within the same family or even the
same patient.
Previously, linkage analyses revealed a
3.7-Mb region on 9p21 associated with fa-
milial ALS/FTLD,3-10 and genome-wide as-
sociation studies suggested a major risk
factor in the same locus for sporadic ALS
and FTLD.11-15 Recently, 2 research groups
independently explained this locus by a
pathological noncoding hexanucleotide
(G4C2)30-1600 repeat expansion in the chro-
mosome 9 open reading frame 72
(C9orf72) gene of unknown function.16,17
Based on the allele frequencies in cases vs
controls, the first studies suggested that ex-
pansions with more than 30 repeats should
be considered pathological, while alleles
with less than 20 repeats are wild type.16
However, a reliable cutoff for the patho-
logical alleles remains to be established by
additional studies (eg, segregation, neu-
ropathological, or functional studies). Fur-
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thermore, the contribution of intermediate-size alleles
(20-29 repeats) to disease pathology has not yet been
evaluated.
The expansion is the most frequent cause of ALS and
FTLD identified to date. In the Finnish population, 46%
of patients with familial ALS, 21% of patients with spo-
radic ALS, and 29% of patients with sporadic FTLD have
the expansion.16 DeJesus-Hernandez et al17 reported the
expansion in 24% of patients with familial ALS, 4% of
patients with sporadic ALS, and 12% of patients with fa-
milial FTLD. In the Flanders-Belgian cohort, the muta-
tion was observed in 47% of patients with familial ALS,
5% of patients with sporadic ALS, and 16% of patients
with familial FTLD.18 The pathological mechanism as-
sociated with the expansion is currently unknown ex-
cept that the expansion leads to a 50% reduction of
C9orf72messenger RNA expression,17,18 and the brain pa-
thology in mutation carriers is associated with possibly
toxic nuclear RNA foci, as well as TAR DNA-binding pro-
tein 43 (TDP-43) and p62 inclusions.17,19 The clinical phe-
notype appears to be highly heterogeneous in reported
mutation carriers.20
Following the discovery of this novel mutation, many
questions are yet to be addressed. What is the expan-
sion frequency in other ALS/FTLD cohorts? Are there any
clinical features that can discriminate between patients
with and without the C9orf72 expansion? What is a re-
liable cutoff for the pathological repeat number? What
is the role of alleles with intermediate repeat sizes or vari-
ability in the region flanking the G4C2 repeat? Could the
expansion account for other neurodegenerative dis-
eases, such as Alzheimer disease (AD) or Parkinson dis-
ease (PD)? These questions were investigated by the cur-
rent study. The expansion frequency was estimated in a
comprehensive case-control sample set consisting of 2224
individuals (patients with FTLD, ALS, AD, and PD and
healthy controls). To our knowledge, this is the first case-
control study using a 2-step genotyping strategy that al-
lowed for the analysis of genotype information for the
alleles with less than 50 repeats. Clinical data were ana-
lyzed to understand the phenotype spectrum observed
in mutation carriers.
METHODS
HUMAN SAMPLES
Informed consent was obtained from all participants in accor-
dance with the respective ethical review boards. Sample char-
acteristics are presented in Table1. All study participants were
either European (from Italy, Spain, and the United Kingdom)
or North American (white individuals mainly of North Euro-
pean origin) recruited from hospitals specializing in neurode-
generative disorders. The investigated unrelated individuals in-
cluded 520 patients with FTLD, 389 patients with ALS, 424
patients with AD, and 289 patients with PD and 602 neuro-
logically healthy controls (65 years). Patients were diag-
nosed using established clinical criteria.21-24 Cases with known
pathological mutations were excluded from the study. How-
ever, a previously described data set of 29 Canadian patients
with PD carrying the common LRRK2 G2019S mutation25 was
analyzed separately for the presence of an expansion or inter-
mediate allele in C9orf72 as a potential modifier of age at on-
set of parkinsonism. In addition, all available family members
of 18 extended pedigrees were genotyped for the G4C2 repeats
(6 FTLD, 9 ALS, 1 PD, and 2 AD families).
GENOTYPING ASSAYS
Genomic DNA was isolated from blood using a QIAGEN kit.
To detect the size of the C9orf72 alleles within the normal to in-
termediate range of G4C2 repeats (detection limit is 50 repeats)
and the presence of large expansions, a 2-step genotyping strat-
egy was used as previously described17 (eFigure 1, http://www
.joygrafika.com/projects/University_of_Toronto). Briefly, in the
first step, DNA samples (10 ng/polymerase chain reaction [PCR])
were amplified using primers near the repeat region (5-FAM-
caaggagggaaacaaccgcagcc and 5-gcaggcaccgcaaccgcag). The frag-
ment-length analysis was performed on an ABI PRISM 3100 DNA
analyzer and visualized by Genotyper software version 2.5 (Ap-
plied Biosystems). Since expanded alleles are not amplifiable with
this set of primers, expansion carriers appear to be homozygous
for a normal repeat allele (in addition to true homozygotes). The
number of repeats was calculated based on the fragment size (eg,
129 base pairs [bp] represents 2 repeats, which was confirmed
by sequencing 7 samples [PCR primers: 5-cgtcatcgca-
catagaaaaca and 5-ggagacagctcgggtactga]). Since published se-
quencing analysis demonstrated that the G4C2 repeats are unin-
terrupted,17 the number of repeats for each allele was calculated
using the following formula: (amplicon length − 117)/6. Samples
Table 1. Sample Characteristics, Including Expansion
Carriers Identified in Each Cohort
Cohort
All
Samples,
No. (%)
No. of
Expansion
Carriersa
Frequency of
Expansion, %
ALS
Age at onset, y,
mean (SD)
57.6 (12.3)
Female 149 (38.3)
Total 389 36 9.3
Familial 47 18 38.3
FTLD
Age at onset, y,
mean (SD)
65.4 (10.1)
Female 258 (49.6)
Total 520 27 5.2
Familial 211 22 10.4
AD
Age at onset, y,
mean (SD)
72.1 (9.4)
Female 264 (62.3)
Total 424 . . . . . .
Familial 167 . . . . . .
PD
Age at onset, y,
mean (SD)
52.6 (13.0)
Female 92 (31.8)
Total 289 2 0.7
Familial 116 1 0.9
Controls
Age, y, mean (SD) 70.2 (9.5)
Female 357 (59.3)
Total 602 . . . . . .
Abbreviations: AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis;
ellipses, not detected/not applicable; FTLD, frontotemporal lobar
degeneration; PD, Parkinson disease
aThe allele was counted as an expansion allele when the number of
repeats was more than 30.
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scored as homozygous were included in the second step to de-
tect large expansions (50 repeats) by a repeat-primed PCR. DNA
samples (100 ng/PCR) were amplified as described previously
using 3 primers (MRX-F: FAM-tgtaaaacgacggccagtcaaggagggaaa-
caaccgcagcc, MRX-M13R: caggaaacagctatgacc, and MRX-R1:
caggaaacagctatgaccgggcccgccccgaccacgccccggccccggccccgg),17 ex-
cept the primer ratio was modified to increase PCR efficiency
(MRX-F/MRX-M13R/MRX-R1 = 5/5/1). Data were analyzed using
GeneScan software version 3.1 (Applied Biosystems).
To search for sequence variability in regions flanking the
G4C2 repeat, 2 PCR products were sequenced in 50 patients (44
expansion carriers and 6 noncarriers) (eFigure 1B). The 5 flank-
ing region was amplified with primers 5-ccctaccagggtttgcagt
and 5-cgactcctgagttccagagc (616 bp). The 3 flanking region
was amplified with primers 5-tgcggttgcggtgcctgc and 5-
gaatggggagcacaccgacttgc (625 bp). The APOE polymorphism
defining the ε2 to ε4 alleles and the 238-bp insertion/deletion
in intron 9 of MAPT defining the H1/H2 haplotypes was geno-
typed as described previously in all patients with FTLD and ALS
with a pathological expansion in C9orf72, as well as in their
family members.26
STATISTICAL ANALYSES
Differences in sample characteristics (eg, sex, age at onset,
and familial history between cases and controls) were ana-
lyzed using the 2 test, Fisher exact test, or independent-
samples t test as appropriate. Allele frequencies within the
normal to intermediate range of repeats were calculated after
excluding patients who carry the pathological expanded allele,
defined as a repeat number more than 30 as previously sug-
gested.16
The association between disease and alleles with less than
30 repeats was assessed using CLUMP software that is based
on Monte Carlo tests for the evaluation of highly polymorphic
loci.27 Empirical P values for T1 through T4 analyses were ob-
tained after 2000 simulations. Further analyses to obtain P val-
ues for each allele were also carried out as follows: allele counts
from cases and controls were tested for significance using the
2 test after combining rare alleles. When any cell in the con-
tingency table had an expected value less than 5, the corre-
sponding allele was pooled with the neighboring allele (this pro-
cess was repeated until no cell had an expected value5). Each
allele group was compared in turn with the rest of the alleles
pooled together to calculate the 2 statistic. The pooling en-
abled the calculation of odds ratios and 95% CIs.28 All the sta-
tistical analyses were done using SPSS (version 20; IBM SPSS).
Statistical significance was taken to be P .05 (Bonferroni cor-
rection for multiple testing was applied).
RESULTS
We used a previously suggested cutoff (30 repeats) to
distinguish the pathogenic expansion from the normal
allele.16 None of the patients in our series were homo-
zygous for the expansion allele, since all samples were
successfully amplified in the first step. Samples homo-
zygous in the first step (33%) were evaluated for the large
expansion (50 repeats). Based on the electrophero-
gram with sawtooth peaks (eFigure 1), 65 unrelated pa-
tients were identified to be expansion carriers: 9.3% of
patients with ALS (36 of 389), 5.2% of patients with FTLD
(27 of 520), and 0.7% of patients with PD (2 of 289), but
no expansions were detected in 424 patients with AD and
602 controls (Table 1).
Details of the clinical data for expansion carriers vs
noncarriers are presented in Table 2. In addition, 14
case reports on expansion carriers are available in the on-
line-only material. The expansion allele was signifi-
cantly associated with family history for both ALS and
FTLD (P  .001). The frequency of the expansion was
10.5% in patients with familial FTLD and 38.3% in pa-
tients with familial ALS. The average age at onset of FTLD
was 6 years younger in expansion carriers than those with-
out (P = .003). The disease subcategory of FTLD with mo-
tor neuron disease was significantly enriched in expan-
sion carriers (P .001). However, there was no significant
association with any evaluated clinical characteristic of ALS.
In expansion carriers, we did not observe an interme-
diate or pathological number of repeats for the second
allele (2-11 repeats). Also, sequencing analysis of 44 ex-
pansion carriers and 6 noncarriers did not reveal vari-
ability in the regions immediately flanking the G4C2 re-
peat that could be responsible for repeat instability,
including a short tandem repeat (CGG)8 located 294 bp
downstream of the G4C2 repeat (eFigure 1B). Hence, it
is unlikely that the number of repeats of the second al-
lele or polymorphisms in the flanking region contribute
significantly to the disease phenotype. In addition, the
MAPT H1/H2 and APOE genotypes were examined in 63
expansion carriers (36 patients with ALS and 27 pa-
tients with FTLD) and their family members, since both
genes are well-known risk factors for several neurode-
generative disorders including FTLD. However, statisti-
cal analysis did not reveal a significant link between these
genes and disease presentation (ALS vs FTLD) (eTable
1 and eFigure 2).
For the segregation analysis, we genotyped all avail-
able family members of probands with the expansion (6
FTLD and 9 ALS families) and detected 30 additional mu-
tation carriers. The expansion allele showed perfect coseg-
regation with disease, and for those expansion carriers
who were asymptomatic (mean [SD] age, 46.3 [10.7]
years; range, 24-64 years), follow-up is ongoing (Table3,
Figure 1A, and eFigure 2A and B). Within the pedi-
grees, there was no evidence of instability in the repeat
size for the normal alleles (Figure 1A and eFigure 2). The
method used in the study did not allow the same ques-
tion to be addressed for the expanded allele, and the DNA
quality/quantity was not sufficient to conduct Southern
blotting to estimate the size of the expanded allele. How-
ever, in the 2 families with expansion carriers in 2 gen-
erations, a younger age at onset in the subsequent gen-
eration was observed (48 vs 74 years in ALS15 pedigree
and 45-47 years vs 60s in the FTLD TOR73 pedigree),
indicating genetic anticipation (eFigure 2A).
Two patients with PD (without signs of ALS or de-
mentia) were categorized as expansion carriers (39 and
32 repeats). Family history of PD was known only for 1
patient; however, the 39-repeat allele does not segregate
with PD, since the affected sibling did not inherit it
(Figure 1B). The role of intermediate alleles (20-29 re-
peats) in neurodegenerative diseases is currently un-
known. The clinical characteristics of the patients with
PD with the expansion and intermediate alleles are pre-
sented in eTable 2. Intermediate alleles were observed
only in 4 PD cases, 2 of which had parkinsonism fol-
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lowed by severe dementia. We also assessed if the pres-
ence of intermediate alleles could influence the age at on-
set of parkinsonism in LRRK2 G2019S mutation carriers
(onset between age 40-80 years). However, none of the
29 LRRK2 mutation carriers had an expanded or inter-
mediate repeat allele (11 repeats).
Furthermore, our results do not suggest that the in-
termediate C9orf72 alleles significantly contribute to AD
risk, since the frequency of such alleles was similar be-
tween patients with AD and controls (about 1%), and the
alleles with 23 and 21 repeats did not segregate with AD
in 2 families (eFigure 2C). Importantly, 15 of the 31 au-
topsied AD cases had TDP-43 inclusions (a frequent co-
pathology in AD); however, no intermediate allele car-
riers were found among these cases. This is of note because
ALS/FTLD caused by the expansion is associated with
TDP-43 brain pathology.17,20,29,30 Hence, the TDP-43 pa-
thology in AD could not be explained by an increased
number of repeats in C9orf72.
Finally, a case-control association analysis was car-
ried out using Monte Carlo tests. All carriers of alleles
with more than 30 repeats were excluded from this analy-
sis to avoid association due to the pathological expan-
sion. Analyses T1 and T2 revealed association between
normal repeat alleles (30) with FTLD and ALS (eTable
4). Analysis T3 showed that the 10-repeat allele was sig-
nificantly associated with FTLD. To get statistics for each
allele (eg, P value or odds ratio), we assessed the distri-
bution of normal alleles in 4 disease groups vs controls
(Figure 2 and eTable 3). In each group, the most fre-
quent were the 2-, 5-, and 8-repeat alleles, which ac-
count for about 75% of all observed alleles. A marginal
protective effect of the 5-repeat allele was detected in
FTLD, ALS, and PD, as well as of the 11-repeat allele in
ALS and AD (nominal P .05). The frequency of the 10-
Table 2. Comparison of the Clinical Statistics Between Expansion Carriers and Noncarriers
Cohort
No. (%)
P Value a ORb (95% CI)Noncarriers Expansion Carriers
ALS Cases
No. of ALS cases 353 36
Age at onset, y, mean (SD) 57.6 (12.6) 57.8 (9.1) .92 . . .
Female 134 (38.0) 15 (41.7) .68 . . .
Familial cases 29 (8.2) 18 (50.0) 2.31  10−9 11.2 (5.2-23.8)
Cases with FTLD 41 (11.6) 4 (11.1) .93 . . .
Site of onset
Limb 235 (66.6) 24 (66.7) .99 . . .
Bulbar 93 (26.3) 10 (28.7) .85 . . .
Mixed 7 (2.0) . . . . . . . . .
Unknown 18 (5.1) 2 (5.6) . . . . . .
FTLD Cases
No. of FTLD cases 493 27
Age at onset, y, mean (SD) 65.7 (10.1) 59.6 (7.6) .003 . . .
Female 248 (50.5) 10 (37.0) .17 . . .
Familial cases 188 (38.1) 22 (81.5) 7.8  10−6 7.1 (2.7-19.2)
Diagnosis subcategory
bvFTD 218 (44.2) 11 (40.7) .72 . . .
FTLD unspecified 131 (26.6) 8 (29.6) .73 . . .
SD 60 (12.2) . . . . . . . . .
PNFA 59 (12.0) . . . . . . . . .
FTLD-MND 20 (4.1) 8 (29.6) 2.8  10−5 10.0c (3.9-25.5)
Other 5 (1.0) . . . . . . . . .
Abbreviations: ALS, amyotrophic lateral sclerosis; bvFTD, behavioral variant of frontotemporal dementia; ellipses, not detected/not applicable; FTLD,
frontotemporal lobar degeneration; FTLD-MND, frontotemporal lobar degeneration with motor neuron disease; OR, odds ratio; PNFA, progressive nonfluent
aphasia; SD, semantic dementia.
aA t test was used to compare the continuous variables. Categorical variables were compared by Pearson 2 test or Fisher exact test (when expected value 5).
bThe OR was calculated only for variables showing P  .05.
cThe OR was obtained by comparing FTLD-MND with the rest of the subcategories.
Table 3. Expansion Carriers Identified in the ALS and FTLD
Pedigrees
Status
Sample Size
All
Expansion
Carriers Noncarriers
6 FTLD
pedigrees
48 20 28
FTLD 8 8 . . .
FTLD-MND 1 1 . . .
bvFTD 2 2 . . .
Relatives 30 9 21
Spouses 7 . . . 7
9 ALS
pedigrees
34 25 9
ALS 7 7 . . .
ALS-FTLD 2 2 . . .
FTLD 1 1 . . .
Relatives 24 15 9
Abbreviations: ALS, amyotrophic lateral sclerosis; bvFTD, behavioral
variant of frontotemporal dementia; ellipses, not detected; FTLD,
frontotemporal lobar degeneration; FTLD-MND, frontotemporal lobar
degeneration with motor neuron disease.
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repeat allele was marginally increased in all 4 neurode-
generative diseases vs the control group (nominal
P  .05). The risk associated with this allele remained
significant in the FTLD data set even after Bonferroni cor-
rection (P = .03; odds ratio, 2.14) (eTable 3).
COMMENT
Our findings further support the expansion in C9orf72
as a common cause of ALS and FTLD, but not AD or PD.
In contrast to the 1-step genotyping used in published
case-control studies of C9orf72, 2-step genotyping al-
lowed us to obtain the exact genotype for each indi-
vidual (except 50 repeats). No homozygous expan-
sion carriers were found in the current study, suggesting
that such a genotype could be lethal. A heterozygous ex-
pansion (30 repeats) was detected in 9.3% of patients
with ALS and 5.2% of patients with FTLD and was sig-
nificantly more frequent in cases with a family history
of ALS or FTLD. The frequency was doubled in our fa-
milial FTLD cases (10.4%), which is similar to that re-
ported by DeJesus-Hernandez et al17 (11.7%).
We did not detect significant association between the
presence of the expansion and clinical characteristics of
patients with ALS, while in the FTLD series, the expan-
sion was associated with a younger age at onset and the
FTLD with motor neuron disease phenotype. These find-
ings are in line with previous observations.18,31 Notably,
none of our FTLD cases with the expansion were diag-
nosed with primary progressive aphasia, which is simi-
lar to the Mayo clinic cohort32 and different from the Man-
chester cohort wherein 4 primary progressive aphasia
cases had the expansion.31 Wide clinical variability in ex-
pansion carriers has been previously described (eg, age
at onset and disease duration),20,33 and future character-
ization of such data in a large cohort of carriers could
generate a clinically useful algorithm to prioritize pa-
tients for mutation analysis of C9orf72.34
In our study, a variable phenotype in expansion car-
riers (ALS vs FTLD) was not associated with the APOE
alleles or the extended MAPT H1/H2 haplotypes. How-
ever, only an evaluation of a large data set could reach a
solid conclusion about APOE and MAPT as phenotype
modifiers. It is also possible that C9orf72 itself is respon-
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Figure 1. Families with the G4C2 repeat expansion. A, Frontotemporal lobar degeneration (FTLD) pedigree. B, Parkinson disease (PD) pedigree. Individual
genotypes are shown beneath the corresponding diamond, including “at-risk” currently asymptomatic individuals. Arabic numbers indicate the repeat units (exp
indicates expansion). The age at the time of examination is shown in the upper right corner. Age at onset is indicated for patients below the ID number. Sex of the
family members is masked to protect privacy.
ARCH NEUROL / VOL 69 (NO. 12), DEC 2012 WWW.ARCHNEUROL.COM
1587
©2012 American Medical Association. All rights reserved.
Downloaded From: http://archneur.jamanetwork.com/ by a Universita Torino User  on 11/19/2015
sible for the modifying effect because of coding se-
quence variations, repeat size, and/or repeat instability.
We demonstrated that the repeat size of the second al-
lele in expansion carriers was within the normal range
(2-11 repeats) and unlikely to contribute to the variabil-
ity in disease phenotype. In addition, our sequencing
analysis did not reveal variations in regions flanking the
G4C2 repeat that could be responsible for repeat insta-
bility or the variable phenotype of expansion carriers. Fu-
ture studies should assess intronic and coding varia-
tions in the entire C9orf72 locus as potential phenotype
modifiers.
Instability of the G4C2 repeat region was suggested to
be a possible mechanism for the occurrence of the ex-
pansion.16 However, a founder effect is more likely to be
responsible for the incidence of the mutation, since most
carriers harbor a common haplotype.17,29 Despite the meth-
od’s limitation (the size of large expansions could not be
determined), we estimated the stability of 2 to 30 re-
peats in the pedigrees. The number of repeats was stable
across generations.
Given the clinical/pathological overlap between neu-
rodegenerative diseases,35-38 our study determined whether
the expansion plays a role in AD or PD. Importantly, the
PD samples were previously collected to generate a data
set enriched in genetic predisposition to PD and mainly
consisted of cases with either an early age at onset (mean
[SD], 52.6 [13.04] years) and/or family history of PD
(40%).39 However, the frequency of expansion alleles in
our PD data set was unremarkable (0.7%). Only 2 pa-
tients (without symptoms of ALS or dementia) were car-
riers of 32 and 39 repeats, which is much smaller than
the expansion estimated by Southern blot (700-1600
repeats),17 and segregation analysis did not support the
pathogenic nature of the 39-repeat allele. This raises con-
cern about a reliable cutoff for a pathological repeat num-
ber, which is important in the utility of genetic screen-
ing in patient care. Likely, a higher cutoff or establishing
a gray zone will be proposed in the future based on an
increasing number of observations from case-control and
neuropathological studies.40,41 Among our ALS and FTLD
mutation carriers, only 2 had an allele with question-
able pathological significance (40 repeats). The con-
nection between the repeat number and pathological sig-
nificance has to be carefully investigated. It is possible
that the pathological cutoff is disease dependent (eg, ALS
vs FTLD) and could be modulated by individual genetic
background. Furthermore, future studies have to test the
possibility of somatic instability of the repeat region (the
disease-related tissues, such as the spinal cord, could have
larger expansions than blood cells from the same indi-
vidual).
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Figure 2. Comparison of the allele frequencies (repeats 30) between controls and cases in each disease cohort (AD indicates Alzheimer disease; ALS,
amyotrophic lateral sclerosis; FTLD, frontotemporal lobar degeneration; and PD, Parkinson disease). Asterisks indicate a significant P value (nominal P  .05). In
comparison with controls, there were 2 significant differences observed for the allele frequencies for the patients with FTLD, 4 for the patients with ALS, 2 for the
patients with AD, and 2 for the patients with PD. A similar pattern was observed for all 4 diseases. The 5-repeat allele was significantly lower in FTLD, ALS, and PD
than in controls and the 10-repeat allele in disease was significantly higher in all 4 disease groups than in controls. Expansion carriers were excluded from this
analysis: controls, n = 602; FTLD, n = 488; ALS, n = 353; AD, n = 424; and PD, n = 287.
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Our results did not suggest that the expansion or in-
termediate alleles are associated with AD. In contrast, there
was a report of 6 expansion carriers in a familial AD co-
hort (1%), 4 of whom were from the same family.42
However, autopsy indicated that 3 carriers actually had
amnestic FTLD. Whether the remaining carriers were also
clinically misdiagnosed as having AD remains to be seen.
In addition to typical AD pathology, 15 of our patients
with AD had TDP-43 inclusions, which are known to be
associated with the brain pathology of the expan-
sion17,20,29,30; however, all of these patients with AD have
genotypes within the normal range (2-12 repeats).
Our case-control studies also assessed the frequency
of alleles within the normal range (30 repeats) and ob-
served a trend toward an association between the 10-
repeat allele and risk for all 4 disorders (odds ratio, 1.72-
2.14). It is tempting to speculate that this allele is in linkage
disequilibrium with an unknown C9orf72 risk varia-
tion. Further genetic work has to validate this observa-
tion, including follow-up case-control studies and se-
quencing of 10-repeat carriers.
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